MedKoo Cat#: 571181 | Name: A-71623

Description:

WARNING: This product is for research use only, not for human or veterinary use.

A 71623 is a selective (Cholecystokinin) CCK-A agonist that suppresses food intakes.

Chemical Structure

A-71623
A-71623
CAS#130408-77-4

Theoretical Analysis

MedKoo Cat#: 571181

Name: A-71623

CAS#: 130408-77-4

Chemical Formula: C44H56N8O9

Exact Mass: 840.4170

Molecular Weight: 840.98

Elemental Analysis: C, 62.84; H, 6.71; N, 13.32; O, 17.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
A 71623; A-71623; A71623
IUPAC/Chemical Name
L-Phenylalaninamide, N-((1,1-dimethylethoxy)carbonyl)-L-tryptophyl-N6-(((2-methylphenyl)amino)carbonyl)-L-lysyl-L-alpha-aspartyl-Nalpha-methyl-
InChi Key
KNHCBYMGWWTGSO-ZYADHFCISA-N
InChi Code
InChI=1S/C44H56N8O9/c1-27-15-9-11-19-31(27)50-42(59)46-22-14-13-21-33(39(56)49-35(25-37(53)54)41(58)52(5)36(38(45)55)23-28-16-7-6-8-17-28)48-40(57)34(51-43(60)61-44(2,3)4)24-29-26-47-32-20-12-10-18-30(29)32/h6-12,15-20,26,33-36,47H,13-14,21-25H2,1-5H3,(H2,45,55)(H,48,57)(H,49,56)(H,51,60)(H,53,54)(H2,46,50,59)/t33-,34-,35-,36-/m0/s1
SMILES Code
O=C(N)[C@H](CC1=CC=CC=C1)N(C([C@H](CC(O)=O)NC([C@H](CCCCNC(NC2=CC=CC=C2C)=O)NC([C@H](CC3=CNC4=C3C=CC=C4)NC(OC(C)(C)C)=O)=O)=O)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 840.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Asin KE, Bednarz L, Nikkel AL, Gore PA Jr, Nadzan AM. A-71623, a selective CCK-A receptor agonist, suppresses food intake in the mouse, dog, and monkey. Pharmacol Biochem Behav. 1992 Aug;42(4):699-704. PubMed PMID: 1513850. 2: Sugg EE, Kimery MJ, Ding JM, Kenakin DC, Miller LJ, Queen KL, Rimele TJ. CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623). J Med Chem. 1995 Jan 6;38(1):207-11. PubMed PMID: 7837233. 3: Lin CW, Shiosaki K, Miller TR, Witte DG, Bianchi BR, Wolfram CA, Kopecka H, Craig R, Wagenaar F, Nadzan AM. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Mol Pharmacol. 1991 Mar;39(3):346-51. PubMed PMID: 1706470. 4: Cannon JB, Adjei LA, Lu MY, Garren K. Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. J Drug Target. 1996;4(2):69-78. PubMed PMID: 8894966. 5: Silvestri S, Lu MY, Johnson H. Kinetics and mechanisms of peptide aggregation. I: Aggregation of a cholecystokinin analogue. J Pharm Sci. 1993 Jul;82(7):689-93. PubMed PMID: 8360841. 6: Bennett MJ, Nikkel AL, Bianchi BR, Miller TR, Bednarz L, Witte DG, Stashko M, Wang SS, Gore PA, Asin KE, et al. CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue. J Med Chem. 1994 May 27;37(11):1569-71. PubMed PMID: 8201591. 7: Gracey DJ, Bell R, King DJ. Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):497-504. PubMed PMID: 11999900. 8: Davidowa H, Wetzel K, Henklein P. Neostriatal neurons of rats can be influenced by cholecystokinin-A receptor agonists. Neuropeptides. 1997 Jun;31(3):231-5. PubMed PMID: 9243519. 9: Asin KE, Gore PA Jr, Bednarz L, Holladay M, Nadzan AM. Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats. Brain Res. 1992 Jan 31;571(1):169-74. PubMed PMID: 1611492. 10: Miller TR, Bianchi BR, Witte DG, Lin CW. Peripheral cholecystokinin type A receptors mediate oxytocin secretion in vivo. Regul Pept. 1993 Jan 22;43(1-2):107-12. PubMed PMID: 8426907. 11: Elliott RL, Kopecka H, Bennett MJ, Shue YK, Craig R, Lin CW, Bianchi BR, Miller TR, Witte DG, Stashko MA, et al. Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus. J Med Chem. 1994 Jan 21;37(2):309-13. PubMed PMID: 8295219. 12: Povoski SP, Zhou W, Longnecker DS, Jensen RT, Mantey SA, Bell RH Jr. Stimulation of in vivo pancreatic growth in the rat is mediated specifically by way of cholecystokinin-A receptors. Gastroenterology. 1994 Oct;107(4):1135-46. Review. PubMed PMID: 7523219. 13: Asin KE, Bednarz L, Nikkel AL, Gore PA Jr, Montana WE, Cullen MJ, Shiosaki K, Craig R, Nadzan AM. Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide. Am J Physiol. 1992 Jul;263(1 Pt 2):R125-35. PubMed PMID: 1636779. 14: Lin CW, Bianchi BR, Miller TR, Witte DG, Wolfram CA. Both CCK-A and CCK-B/gastrin receptors mediate pepsinogen release in guinea pig gastric glands. Am J Physiol. 1992 Jun;262(6 Pt 1):G1113-20. PubMed PMID: 1616041. 15: Gué M, Tekamp A, Tabis N, Junien JL, Buéno L. Cholecystokinin blockade of emotional stress- and CRF-induced colonic motor alterations in rats: role of the amygdala. Brain Res. 1994 Sep 26;658(1-2):232-8. PubMed PMID: 7834346. 16: Davidowa H, Wetzel K, Vierig G. Effects of cholecystokinin agonists on striatal neurons are reduced by acetylcholine. Peptides. 1997;18(4):541-5. PubMed PMID: 9210173. 17: Dezube M, Sugg EE, Birkemo LS, Croom DK, Dougherty RW Jr, Ervin GN, Grizzle MK, James MK, Johnson MF, Mosher JT, et al. Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands. J Med Chem. 1995 Aug 18;38(17):3384-90. PubMed PMID: 7650691. 18: Gué M, del Rio C, Junien JL, Buéno L. Interaction between CCK and opioids in the modulation of the rectocolonic inhibitory reflex in rats. Am J Physiol. 1995 Aug;269(2 Pt 1):G240-5. PubMed PMID: 7653564. 19: Giralt M, Vergara P. Inhibition by CCK of ascending contraction elicited by mucosal stimulation in the duodenum of the rat. Neurogastroenterol Motil. 2000 Apr;12(2):173-80. PubMed PMID: 10877605. 20: Shiosaki K, Lin CW, Kopecka H, Craig R, Wagenaar FL, Bianchi B, Miller T, Witte D, Nadzan AM. Development of CCK-tetrapeptide analogues as potent and selective CCK-A receptor agonists. J Med Chem. 1990 Nov;33(11):2950-2. PubMed PMID: 1700123.